Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
сне 2006 · John Wiley & Sons
Электронная кніга
391
Старонкі
reportАцэнкі і водгукі не спраўджаны Даведацца больш
Пра гэту электронную кнігу
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
Звесткі пра аўтара
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Ацаніце гэту электронную кнігу
Падзяліцеся сваімі меркаваннямі.
Чытанне інфармацыb
Смартфоны і планшэты
Усталюйце праграму "Кнігі Google Play" для Android і iPad/iPhone. Яна аўтаматычна сінхранізуецца з вашым уліковым запісам і дазваляе чытаць у інтэрнэце або па-за сеткай, дзе б вы ні былі.
Ноўтбукі і камп’ютары
У вэб-браўзеры камп’ютара можна слухаць аўдыякнігі, купленыя ў Google Play.
Электронныя кнiгi i iншыя прылады
Каб чытаць на такіх прыладах для электронных кніг, як, напрыклад, Kobo, трэба спампаваць файл і перанесці яго на сваю прыладу. Выканайце падрабязныя інструкцыі, прыведзеныя ў Даведачным цэнтры, каб перанесці файлы на прылады, якія падтрымліваюцца.
